An interventional study of JOCOAT(TM) APN-3003 in Surgical Adhesions, sponsored by ARC Medical Inc.. Not yet recruiting. Open to participants aged 15 Years to 25 Years. Per ClinicalTrials.gov, last updated 2025-09-02.
Sponsored by ARC Medical Inc. · Not applicable, Interventional, and Prevention
This study will assess the safety and efficacy of a new liquid anti-adhesion device, JOCOAT(TM) APN-3003 in patients undergoing knee anterior cruciate ligament reconstruction (ACLR) surgery.
This is a single-center, prospective study. Safety and clinical outcomes will be compared with historical controls from enrolled study site patients from NCT03935750 (STABILITY 2) which has evaluated outcomes following ACL rupture in young athletes.
A maximum of 24 patients aged 15-25 years undergoing primary anatomic ACLR with quadriceps tendon (QT) graft following a standardized surgical treatment algorithm will be enrolled. All patients will receive JOCOAT(TM) APN-3003 at the end of their surgery.
121 studies on the registry are indexed under Tissue Adhesions; 15 are open to participants now.
This study's planned enrollment of 24 is below the median of 61 across 84 interventional studies indexed under Tissue Adhesions.
Browse Tissue Adhesions studies →This is the only study on the registry with ARC Medical Inc. as lead sponsor.
Counted across the registry records on this site, refreshed daily.
Pre-operative Inclusion Criteria:
At least two of the following factors that are associated with a high risk of graft failure:
Pre-operative Exclusion Criteria:
Intra-operative Inclusion Criteria:
- Patient undergoes primary anatomic anterior cruciate ligament reconstruction surgery with quadriceps tendon (QT) graft
Intra-operative Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Intra-articular injection
Device: JOCOAT(TM) APN-3003
10 mL of JOCOAT(TM) APN-3003 is applied at the end of surgery
Safety of JOCOAT(TM) APN-3003 as measured by number and severity of adverse device effects and serious adverse device effects
The number of severe and serious adverse events in treated subjects from this study is compared with the number seen in historical controls
Time frame: 3 months after surgery
Exploratory efficacy of JOCOAT(TM) APN-3003 as measured by comparing range of motion (ROM) pre-operatively and post-operatively
Range of motion is measured pre-operative and post-operatively and compared
Time frame: 3 months after surgery
Patient recovery as measured by Patient Reported Outcome Measures (KOOS)
Patient reported outcome measure results (Knee Injury and Osteoarthritis Outcome Score (KOOS) questionnaire) pre-operatively and post-operatively are compared with historical controls
Time frame: Up to 12 months after surgery
Patient recovery as measured by Patient Reported Outcome Measures (PASS)
Patient reported outcome measure results (Patient-Acceptable Symptom States (PASS) questionnaire) pre-operatively and post-operatively are compared with historical controls
Time frame: Up to 12 months after surgery
Patient recovery as measured by Patient Reported Outcome Measures (EQ-5D-5L)
Patient reported outcome measure results (EQ-5D-5L questionnaire) pre-operatively and post-operatively are compared with historical controls
Time frame: Up to 12 months after surgery
No study locations are listed for this record.
Start is estimated for Sep 2025; primary completion for Aug 2026, 11 months later.
Of 35 interventional studies with no phase under Tissue Adhesions, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 34. This study's planned 11 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.